Lusedra
(Fospropofol 12)PreclinicalSmall molecule
EisaiLusedra is one of 38 small molecule programs targeting Effectiveness. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
37
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
73 competitors in Effectiveness
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPhase 3
Mounjaro
Eli LillyPhase 3
Actos
TakedaPhase 3
Nicotine Free Cigarettes
PfizerPhase 3
Botulinum Toxin a
GSKPhase 3
Droxia
TTheravia
Phase 2
Gemzar
Johnson & JohnsonPhase 2
Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Pneumococcal Conjugate Vaccine
NovartisPhase 3
Silver Diamine Fluoride
TThe University of Hong Kong
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 12, 2008
LUSEDRA
NDA NDA022244
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fospropofol 12. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]